Find and Pitch Jounalists, Get Your Story Covered

Tags: lung cancer EGFR-mutated amivantamab exon insertion

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Amivantamab plus lazertinib shows survival benefit in lung cancer - 14 days ago Mitazalimab shows promising survival rates in cancer study - about 1 month ago Amgen’s lung cancer treatment gets conditional approval - 3 months ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer - about 2 months ago FDA Approves Zanidatamab for Biliary Tract Cancer - 5 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 7 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 8 months ago A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu - about 1 year ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - over 1 year ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance - 2 months ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease - 3 months ago Avutometinib Plus Defactinib Moves One Step Closer to Approval for Treatment of Ovarian Cancer - 3 months ago FDA Grants Priory Review for Human Monoclonal Antibody Drug to Treat Muscle-Invasive Bladder Cancer - 4 months ago CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC - 5 months ago FDA Grants Priority Review for Durvalumab to Treat Small Cell Lung Cancer - 8 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - about 1 year ago
5	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study - 4 months ago Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 7 months ago FDA Approves Axatilimab-csfr for cGVHD - 8 months ago
6	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Inebilizumab for Myasthenia Gravis Reduces Steroid Burden - 5 months ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 9 months ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 9 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - over 1 year ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - over 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - over 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - over 1 year ago What's New in Targeted Lung Cancer Treatment? - over 1 year ago
7	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 5 months ago
8	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis - 6 months ago
9	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 7 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 8 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 10 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - about 1 year ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - about 1 year ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - about 1 year ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - about 1 year ago Biogen Reprioritizes Alzheimer Disease Franchise, Discontinuing Aducanumab and Advancing Lecanemab - about 1 year ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - over 1 year ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - over 1 year ago FDA Approves Capivasertib With Fulvestrant for PIK3CA/ALT1/PTEN Alterations Breast Cancer - over 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - over 1 year ago Subcutaneous Lecanemab Demonstrates Greater Amyloid Plaque Removal Than Intravenous Lecanemab - over 1 year ago
10	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug - 7 months ago

Journalists covering amivantamab